Login to Your Account



FDA OKs Narrower Indication for Forest Lab's COPD Drug

By Marie Powers


Wednesday, March 2, 2011
After a long and winding road, the FDA has at last given Forest Laboratories Inc. the green light to market Daliresp (roflumilast) in the U.S. to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of such flare-ups, which may include breathlessness, chronic cough and excessive production of phlegm leading to medical intervention, including hospitalization.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription